Latest news with #NeuroEMTherapeutics
Malaysian Reserve
6 days ago
- Health
- Malaysian Reserve
CareONE Concierge Now Accepting Candidates for Alzheimer's Device Study
Study offers patients the opportunity to try an experimental, non-drug therapy for Alzheimer's using an FDA-designated Breakthrough Device ATLANTA, July 10, 2025 /PRNewswire/ — CareONE Concierge has announced the launch of a new research study to evaluate an innovative wearable device aimed at addressing cognitive symptoms associated with Alzheimer's-related dementia. The study will utilize NeuroEM Therapeutics'® TEMT-RF cap, a non-invasive device that has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). Alzheimer's disease is a growing global health crisis, affecting nearly 7 million Americans and is projected to impact nearly 13 million by 2050. Despite decades of research, treatment options remain limited, with most current therapies only addressing symptoms rather than the underlying causes of cognitive decline. NeuroEM Therapeutics is pioneering Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF) as a potentially groundbreaking approach to treating the disease at its root. The lightweight, wearable device delivers electromagnetic waves similar to those produced by cell phone signals from multiple emitters. It is being investigated for its potential to break apart toxic protein oligomers within neurons throughout the brain. These oligomers—clusters of beta-amyloid and tau proteins—are thought to drive the progression of Alzheimer's disease. By disrupting these harmful accumulations, TEMT-RF may help restore neuronal function and slow cognitive decline. 'We all know friends and family members who have been impacted by Alzheimer's or dementia,' said Peter Bechtel, CEO of CareONE Concierge. 'This study represents a potential turning point in the fight against these devastating conditions. By participating in this study, individuals have the opportunity to experience cutting-edge, non-drug therapy while contributing to groundbreaking advancements in Alzheimer's treatment.' This study is independently conducted by CareONE Concierge and is designed for individuals with mild to moderate Alzheimer's-related dementia. Participants will be required to wear the device twice daily for one hour, follow a structured research protocol, and complete cognitive assessments throughout the study. Dr. Edward Goodwin, Chief Scientist at NeuroEM, emphasized the scientific foundation behind TEMT-RF, stating, 'Our research has shown that TEMT-RF has the potential to impact the key biological processes associated with Alzheimer's disease. This study will help us gather more real-world data on how the device affects cognitive function and overall brain health.' 'NeuroEM is excited to partner with CareONE Concierge,' stated Chuck Papageorgiou, CEO of NeuroEM Therapeutics. 'Our objective is to promote safe, effective, and non-invasive technologies for cognitive health, and research initiatives like this are essential in helping us uncover the full potential of TEMT-RF. With Alzheimer's cases increasing, innovative research such as this provides new hope for patients, caregivers, and the future of cognitive health. Together, we can take meaningful steps toward a future where memory loss is no longer an inevitable part of aging.' CareONE Concierge is now accepting qualified participants for the study. For more information or to apply, please email CT@ or apply at About CareONE ConciergeCareONE Concierge is committed to delivering Preventative Healthcare solutions that meet the needs of patients, providers, and the healthcare system. The company works with physicians, patients, and healthcare systems to develop turnkey solutions that increase patient outcomes while enhancing revenue and quality metrics. To learn more, visit . About NeuroEM Therapeutics®NeuroEM Therapeutics is leading the way in the development and clinical testing of bioengineered technology to reverse the cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF), the company received the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease. NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology. To learn more, visit Media Contact:Wendy Stevens, Study Manager(919) 600-9930wstevens@
Indianapolis Star
13-06-2025
- Business
- Indianapolis Star
NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer's Treatment
TAMPA, FL / ACCESS Newswire NeuroEM Therapeutics ®, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer's disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with The Series A round supports continued progress toward commercialization of NeuroEM's Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or Alzheimer's and other neurodegenerative diseases. 'BlueLake's support demonstrates the importance of maintaining our momentum in the execution of key clinical, regulatory, and commercial milestones on our journey toward a safe, effective, drug-free treatment for Alzheimer's dementia and other neurodegenerative diseases,' says Chuck Papageorgiou, CEO of NeuroEM Therapeutics. 'It fuels the tireless efforts of our researchers, clinicians, engineers, and the entire NeuroEM team to restore the hope and dignity Alzheimer's disease has already stolen from millions and to one day prevent millions more from facing this devastating diagnosis.' The equity round is led by BlueLake Partner Jamie Rutledge, who also joins the NeuroEM Board of Directors. Rutledge focuses on early-stage investments in breakthrough technologies at BlueLake and is a seasoned technology investor and executive with deep expertise in strategic investment and innovation across the medical technology and consumer electronics sectors. He brings over 25 years of experience to NeuroEM, including senior leadership roles at Dyson and Lenovo. He previously led Lenovo's Strategic Venture Capital and Open Innovation initiatives and directed technology scouting and strategic investments at Dyson. 'NeuroEM's pioneering, non-invasive approach to treating and preventing Alzheimer's represents exactly the kind of patented, deep tech innovation we champion at BlueLake – transformative, defensible, and grounded in scientific rigor. This approach to drug-free treatment and prevention of Alzheimer's holds tremendous promise in tackling a disease that has eluded effective solutions for decades,' said Rutledge. 'We're proud to support the advancement of this groundbreaking technology, and I'm personally honored to help guide NeuroEM as it brings innovative, non-invasive therapies to the forefront of neurodegenerative care.' Adds Papageorgiou, 'Jamie's background in radio frequency systems, embedded devices, and product development aligns closely with our core technology, and his strategic insight will be a valuable asset as NeuroEM moves toward commercialization and broader market engagement.' NeuroEM Therapeutics, a member of StartUp Health's Alzheimer's Moonshot Community ™, is committed to developing, clinically testing, and marketing its multi-patented TEMT-RF technologies that target and reduce cognitive decline and restore immune balance in the brain and blood while boosting energy production in brain cells – critical elements for optimal cognitive function. Early studies have demonstrated that, as an Alzheimer's treatment, TEMT-RF is safe, enhances cognitive function, and may potentially modify the disease itself. The company's first commercial product, a lightweight cap designed for at-home use, is currently under development and has shown extraordinary promise in preclinical and clinical studies. Worn for an hour twice daily, the device uses short pulses of energy in specific ultra-high frequencies to deliver a transcranial electromagnetic treatment that improves key physical factors in the brain at the root of cognitive decline. BlueLake Ventures invests in applied deep tech for the future of work and health, technology defined by significant barriers to entry, such as strong patent protection or specialized domain expertise. Its team consists of experienced operators who have built and scaled startup companies, held executive positions in multi-national corporations, built partnerships between startups and corporations, and deployed strategic venture capital in technology-driven businesses. By leveraging its expertise, resources, and networks, BlueLake aims to accelerate the growth of deep tech innovations that empower both businesses and consumers. About NeuroEM Therapeutics ® NeuroEM Therapeutics is leading the way in the development and clinical testing of bioengineered technology to reverse the cognitive decline associated with Alzheimer's disease and other neurodegenerative conditions. Built upon a decade of groundbreaking research conducted at Tampa-based research facilities at the University of South Florida (USF), the company received the first Breakthrough Device status from the U.S. Food and Drug Administration (FDA) to treat Alzheimer's disease. NeuroEM's continued dedication to cutting-edge research is bringing to market a first-in-class wearable device designed for in-home use to extend healthy longevity using patented Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technology. To learn more, visit Media Contact: Liz Goar NPC Creative Services liz@ SOURCE: NeuroEM Therapeutics View the original press release on ACCESS Newswire
